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Between October 2012 and August 2014, several Swiss 
patients developed severe soft tissue infections due to 
rapidly growing mycobacteria following cosmetic sur-
gery in the Dominican Republic, Ecuador and Mexico. 
Infections were caused by Mycobacterium absces-
sus (n=5), Mycobacterium sp. JAN1 (n=1) and M. con-
ceptionense (n=1). Similar cases may have remained 
unrecognised due to a lack of notification require-
ments. Microbiological work-up of medical tourists 
with infections following cosmetic surgery should 
include rapidly growing mycobacteria. 
Between October 2012 and August 2014, the Swiss 
National Reference Centre for Mycobacteria identified 
a series of severe healthcare-associated soft-tissue 
infections caused by rapidly growing mycobacteria 
(RGM) in seven female Swiss citizens who had under-
gone cosmetic surgery in the Dominican Republic, 
Ecuador and Mexico. Here we report the clinical pres-
entation and microbiological findings and discuss pos-
sible implications for medical tourists and healthcare 
providers.
Case series
Between October 2012 and August 2014, seven previ-
ously healthy female patients sought medical advice 
at different hospitals in the German-, French- and 
Italian-speaking parts of Switzerland due to severe 
healthcare-associated infections following cosmetic 
surgery. All patients were Swiss citizens of Latin 
American descent between 19 and 52 years of age. The 
patients were not related to each other and there was 
no history of contact between them. All patients had 
recently undergone plastic surgery as medical tourists 
in the Dominican Republic (five patients), Ecuador (one 
patient) and Mexico (one patient). Surgical procedures 
performed were abdominal liposuction (two patients), 
breast augmentation (two patients) and breast reduc-
tion with or without simultaneous abdominoplasty 
(three patients). The patients developed post-surgical 
wound infections with symptoms ranging from local 
inflammation to painful subcutaneous and severe deep 
tissue abscesses that failed to respond to initial antibi-
otic chemotherapy.
Microbiological investigations
Microbiological cultures and 16S rRNA gene analyses 
performed on tissue biopsies or drainage fluid from 
the infected sites repeatedly identified RGM as the 
infectious agent, namely Mycobacterium abscessus 
subsp. abscessus (four patients), M. abscessus subsp. 
massiliense (one patient), Mycobacterium sp. JAN1 
(closely related to M. abscessus, one patient) and M. 
conceptionense (M. fortuitum group, one patient) [1,2]. 
Drug susceptibility testing was performed according to 
standard procedures [3]. Minimal inhibitory concentra-
tions (MICs) were as follows: amikacin 0.5–8.0 mg/L; 
clarithromycin <0.5 mg/L for M. abscessus subsp. 
massiliense, Mycobacterium sp. JAN1, and M. con-
ceptionense, inducible resistance due to a functional 
Erm(41) methylase for three of the four M. abscessus 
subsp. abscessus isolates [4]; linezolid 1.0–16.0 mg/L; 
moxifloxacin 2.0–8.0 mg/L for M. abscessus spp. and 
Mycobacterium sp. JAN1, and 0.125 mg/L for M. concep-
tionense; doxycycline 64–>256 mg/L for M. abscessus 
spp. and Mycobacterium sp. JAN1, and <0.5 mg/L for M. 
conceptionense; tigecycline 0.5–8.0 mg/L.
Treatment
All infections required surgical revision in combination 
with multidrug antibiotic chemotherapy, and removal 
of breast implants in two patients. As only mycobac-
terial cultures isolated in different laboratories were 
referred to us and medical records were not available, 
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further details on administered antimicrobials and on 
outcome could not be obtained for six patients. One 
patient (Figures 1 and 2), for whom complete follow-up 
information was available, was treated with a combi-
nation of amikacin, linezolid and moxifloxacin follow-
ing surgical resection and debridement. Macrolides 
were not administered because of an inducible resist-
ance phenotype. Due to serious side effects, amikacin 
and linezolid were stopped after four and five weeks, 
respectively. Moxifloxacin was given for an additional 
week but was stopped thereafter, because of the risk 
of high-level resistance when given as monother-
apy. Ten months later, the patient still had transitory 
nodular skin lesions. Histopathological analyses of 
three lesions showed granulomatous inflammation. 
However, microbiological cultures and PCR from corre-
sponding specimens remained negative.
Transmission history
In order to identify possible transmission links between 
the four patients with confirmed M. abscessus subsp. 
abscessus infection, molecular typing was performed 
using both randomly amplified polymorphic DNA 
(RAPD) PCR and multilocus sequence typing (based 
on partial sequences of the argH, cya, glpK, gnd, 
murC, pta, and purH genes) [5,6]. A clonal relationship 
between the four M. abscessus subsp. abscessus iso-
lates was excluded. In addition, available information 
did not indicate an association of the infections with 
one particular clinic. Several sources can be consid-
ered that may have been responsible for the infections 
such as contaminated rinsing fluids, gentian violet for 
marking skin incisions, injectable medications, anti-
septic solutions, unsterile surgical instruments or poor 
wound aftercare, e.g. by using contaminated tap water 
to irrigate postoperative wounds [7-10]. The Swiss 
health authorities have been informed in order to con-
duct further epidemiological investigations and to con-
tact the health authorities in the affected countries.
Background
Similar to other RGM, M. abscessus can be isolated 
from a wide variety of environmental sources includ-
ing water and soil [11,12]. M. abscessus is considered 
an emerging pathogen causing severe infections in 
patients suffering from chronic pulmonary diseases, 
e.g. bronchiectasis and cystic fibrosis [13]. It has 
also been associated with infections following cos-
metic procedures, e.g. tattooing [14], and with surgi-
cal wound infections, post-injection abscesses and 
healthcare-related outbreaks [15,16]. Antibiotic ther-
apy of M. abscessus infections is challenging due to 
the organism’s natural resistance to most clinically 
available antibiotics [17-19]. Studies on clinical out-
come with respect to specific therapeutic regimens are 
scarce and mainly focus on pulmonary disease [20,21]. 
Antimicrobial chemotherapy of M. abscessus infections 
is guided by in vitro drug susceptibility testing results 
and should include a macrolide, e.g. clarithromycin or 
azithromycin, and an aminoglycoside, preferably ami-
kacin [3,13,19]. Some M. abscessus isolates show an 
inducible macrolide resistance phenotype conferred 
by a ribosomal methylase, Erm(41), and the clinical 
efficacy of macrolides against such strains remains 
unclear [4]. Acquired high-level resistance to mac-
rolides (MICs>256 mg/L), however, is due to mutations 
in the 23S ribosomal RNA gene [22-24]. For extensive 
extrapulmonary disease, administration of additional 
compounds, e.g. moxifloxacin, linezolid and/or tigecy-
cline is recommended [13,15,17,19]. Surgical revision of 
the infected tissues is often necessary to reduce the 
bacterial load at the site of infection.
Other ubiquitous RGM species like M. conceptionense, 
a member of the M. fortuitum group, have also been 
reported to cause infections following medical or cos-
metic procedures [15,25-27]. Treatment is generally 
more effective than against M. abscessus infections 
due to the less pronounced innate antibiotic resist-
ance [28]. Thus, fluoroquinolones show comparably 
low MICs against species in the M. fortuitum group and 
Figure 1
Purulent lesions following abdominoplasty at a medical 
centre in Ecuador, caused by Mycobacterium abscessus 
subsp. abscessus, Switzerland, October 2013
Figure 2
Abdominal computed tomography scan of a patient 
following abdominoplasty at a medical centre in Ecuador 
showing multifocal subcutaneous abscesses of the anterior 
abdominal wall, Switzerland, October 2013
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doxycycline, a tetracycline antibiotic, is effective in 
vitro against about 50% of M. fortuitum group isolates 
[13,17].
Discussion
Previous studies described serious post-surgical com-
plications due to M. abscessus infections following cos-
metic surgery among 20 American ‘lipotourists’ in the 
Dominican Republic between 2003 and 2004 [29-31]. 
Part of the infections were caused by identical strains 
following surgical procedures performed at the same 
clinic, which led to an on-site investigation by national 
public health authorities. However, the cause for this 
outbreak has not been reported. A literature search 
did not reveal any reports on similar infections related 
to medical tourism to the Dominican Republic or other 
Latin American countries during the following years 
with the exception of a large M. abscessus outbreak 
affecting 311 patients who underwent various surgi-
cal procedures including mammoplasty and liposuc-
tion in Belém (Brazil) between February 2004 and June 
2005 [32]. A recent warning published by Schnabel 
et al. after 16 female United States residents under-
went plastic surgery at eight clinics in the Dominican 
Republic between March 2013 and April 2014 [33] as 
well as our case series indicate that the problem is 
either unresolved or that a new source of RGM infec-
tions has emerged. Our observations highlight that 
cases are not restricted to the Dominican Republic and 
that patients residing outside the Americas are also 
affected.
Since RGM infections do not require compulsory report-
ing to public health authorities, the number of unre-
ported cases may be considerable. We recommend that 
microbiological work-up of medical tourists with infec-
tions following cosmetic surgery should always include 
RGM. Furthermore, attending physicians should seek 
expert advice to timely prescribe antibiotic ther-
apy and to prevent the emergence of drug-resistant 
subpopulations.
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